SKYE
Skye Bioscience·NASDAQ
--
--(--)
--
--(--)
3.52 / 10
Netural
Analyst view is dominated by one Strong‑Buy, yet its historical win rate is 0%, reflecting weak confidence. Fund‑flow score is 7.04/10, with small‑cap inflows positive but medium to extra‑large blocks negative, indicating mixed capital interest despite overall good flow.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-09-30
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for SKYE?
- SKYE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.52/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
